EU endorses copy of Enbrel arthritis drug from Samsung, Biogen
Advertisement
A copy of the blockbuster biotech arthritis drug Enbrel was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light from the continent's regulators.
The European Medicines Agency (EMA) said its experts backed the use of South Korean company Samsung Bioepis's version of etanercept, as Enbrel is known scientifically, for rheumatoid arthritis and other autoimmune diseases.
The drug will be sold in Europe by U.S. biotechnology group Biogen.
Cut-price biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their use than the United States, offering savings to healthcare systems and threatening sales by companies making the original products.
Antibody drugs are the big prize for biosimilars because these products are huge sellers, led by AbbVie's market-leading rheumatoid arthritis drug Humira.
The European Medicines Agency (EMA) said its experts backed the use of South Korean company Samsung Bioepis's version of etanercept, as Enbrel is known scientifically, for rheumatoid arthritis and other autoimmune diseases.
The drug will be sold in Europe by U.S. biotechnology group Biogen.
Cut-price biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their use than the United States, offering savings to healthcare systems and threatening sales by companies making the original products.
Antibody drugs are the big prize for biosimilars because these products are huge sellers, led by AbbVie's market-leading rheumatoid arthritis drug Humira.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.